Arrivent Biopharma Inc (AVBP) Stock Price, Quote & News

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology

Sector: Healthcare

Phone: 628 277 4836

Website: arrivent.com

Address:

18 Campus Boulevard, Suite 100, Newtown Square, United States

justiceforb_85 May. 29 at 7:18 PM

$AVBP likely the reason for this to be soaring: https://www.nejm.org/doi/full/10.1056/NEJMoa2604461?query=featured_home.

0 · Reply

Quantumup May. 29 at 4:05 PM

Truist assumed coverage on $AVBP at a Buy rating and a $45 PT (was $43) and said that it views AVBP's firmonertinib as well-positioned across the EGFR Ex20ins and PACC mutation NSCLC landscape. $ORIC JNJ BDTX $CGEM Truist added that its view is supported by an encouraging efficacy and tolerability profile that underpins their $1.1B peak revenue estimate.

0 · Reply

notreload_ai May. 29 at 3:22 PM

Truist is bullish on $AVBP, rating Buy and seeing firmonertinib as a strong lung cancer drug with up to $1.1B peak sales. https://notreload.xyz/xy/truist-initiates-buy-on-arrivent-with-45-price-target/

0 · Reply

laaarsas May. 29 at 2:05 PM

$AVBP why up?

2 · Reply

BossTrade May. 26 at 1:10 AM

$AVBP $BDTX Time to load bdtx

1 · Reply

waugusti May. 25 at 2:35 PM

$BDTX Only competition in 1st line non classical EGFR mutations is Arrivent $AVBP. They are running a phase3 trial in 1st line PACC Mutations only. First Patient dosed in Dec 2025. $BDTX is well positioned in this upcoming 2 billion $ market to grab all or half of it. MC $AVBP: 1,25 B MC $BDTX: 0,15 B A buyout might happen before YE after the FDA gives green light for a P3 trial.

1 · Reply

Monkey7779192 May. 25 at 1:38 PM

$AVBP Why is it trending?

2 · Reply

laaarsas May. 25 at 12:56 PM

$AVBP Did you all do it? Contact them and ask for the SAP?

0 · Reply

laaarsas May. 15 at 1:00 PM

$AVBP Where is the SAP for FURVENT?

0 · Reply

judgeyoung2 May. 13 at 9:38 PM

$AVBP they’re sticking to mid 2026 guidance for data

0 · Reply

ArriVent Biopharma assumed with a Buy at Truist

2026-05-13T10:44:40.000Z - 17 days ago

ArriVent Biopharma price target lowered to $43 from $45 at Citi

2026-05-11T21:38:55.000Z - 19 days ago

ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)

May 11, 2026, 4:01 PM EDT - 19 days ago

ArriVent BioPharma Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 19 days ago

ArriVent BioPharma Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 19 days ago

ArriVent BioPharma Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 19 days ago

ArriVent BioPharma Slides: Corporate presentation

2026-05-07T18:45:02.000Z - 23 days ago

ArriVent Biopharma announces FDA clearance of ARR-002 NDA

May 7, 2026, 8:00 AM EDT - 23 days ago

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

ArriVent BioPharma Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

ArriVent BioPharma Proxy statement: Proxy filing

2026-04-24T11:06:33.000Z - 5 weeks ago

Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’

2026-03-23T12:51:34.000Z - 2 months ago

ArriVent Biopharma price target raised to $45 from $37 at B. Riley

Mar 17, 2026, 5:00 PM EDT - 2 months ago

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

2026-03-11T20:28:14.000Z - 2 months ago

ArriVent Biopharma assumed with a Buy at BTIG

2026-03-06T12:53:00.000Z - 3 months ago

ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer

2026-03-06T11:15:50.000Z - 3 months ago

ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright

2026-03-06T11:00:30.000Z - 3 months ago

ArriVent Biopharma price target raised to $33 from $31 at Citi

Mar 5, 2026, 4:01 PM EST - 3 months ago

ArriVent BioPharma Reports Full Year 2025 Financial Results

Mar 5, 2026, 9:30 AM EST - 3 months ago

ArriVent BioPharma Annual report: Q4 2025

Mar 5, 2026, 9:30 AM EST - 3 months ago

ArriVent BioPharma Earnings release: Q4 2025

2026-02-17T15:25:37.000Z - 3 months ago

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

ABR AESI APO DMAC ET GEHC MANU

2025-12-22T21:20:44.000Z - 5 months ago

ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

2025-12-22T13:06:00.000Z - 5 months ago

ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study

Dec 22, 2025, 8:00 AM EST - 5 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

2025-12-10T11:46:01.000Z - 6 months ago

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

2025-12-10T11:40:54.000Z - 6 months ago

ArriVent Biopharma initiated with a Buy at BTIG

2025-11-25T11:25:25.000Z - 6 months ago

ArriVent Biopharma initiated with a Buy at Truist

2025-11-11T19:40:25.000Z - 7 months ago

ArriVent Biopharma management to meet virtually with Clear Street

2025-11-11T11:35:58.000Z - 7 months ago

ArriVent Biopharma price target lowered to $31 from $33 at Citi

2025-11-10T13:05:18.000Z - 7 months ago

ArriVent Biopharma reports Q3 EPS (83c), consensus (78c)

Nov 10, 2025, 8:00 AM EST - 7 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 7 months ago

ArriVent BioPharma Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 7 months ago

ArriVent BioPharma Quarterly report: Q3 2025

Sep 22, 2025, 4:05 PM EDT - 8 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Aug 11, 2025, 8:00 AM EDT - 10 months ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 8:00 AM EDT - 10 months ago

ArriVent BioPharma Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

ArriVent BioPharma Earnings release: Q2 2025

Jul 21, 2025, 8:00 AM EDT - 11 months ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 1, 2025, 11:15 PM EDT - 11 months ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 11 months ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Transcript: Study Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Press release: Study Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Slides: Study Update

Jun 23, 2025, 7:00 AM EDT - 1 year ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 20, 2025, 4:05 PM EDT - 1 year ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Annual report: Q4 2024

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q3 2024

Nov 6, 2024, 8:30 AM EST - 1 year ago

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

CGON UPB

Sep 9, 2024, 12:05 PM EDT - 1 year ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aug 15, 2024, 7:01 AM EDT - 1 year ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 14, 2024, 4:01 PM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:00 PM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 1 year ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Jun 5, 2024, 7:00 AM EDT - 2 years ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

May 16, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 8, 2024, 8:00 AM EDT - 2 years ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Earnings release: Q1 2024

Apr 22, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints Kristine Peterson to its Board of Directors

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

justiceforb_85 May. 29 at 7:18 PM

$AVBP likely the reason for this to be soaring: https://www.nejm.org/doi/full/10.1056/NEJMoa2604461?query=featured_home.

0 · Reply

Quantumup May. 29 at 4:05 PM

0 · Reply

notreload_ai May. 29 at 3:22 PM

0 · Reply

laaarsas May. 29 at 2:05 PM

$AVBP why up?

2 · Reply

BossTrade May. 26 at 1:10 AM

$AVBP $BDTX Time to load bdtx

1 · Reply

waugusti May. 25 at 2:35 PM

1 · Reply

Monkey7779192 May. 25 at 1:38 PM

$AVBP Why is it trending?

2 · Reply

laaarsas May. 25 at 12:56 PM

$AVBP Did you all do it? Contact them and ask for the SAP?

0 · Reply

laaarsas May. 15 at 1:00 PM

$AVBP Where is the SAP for FURVENT?

0 · Reply

judgeyoung2 May. 13 at 9:38 PM

$AVBP they’re sticking to mid 2026 guidance for data

0 · Reply

laaarsas May. 8 at 6:57 PM

$AVBP EMAIL THEM. ASK THEM. DEMAND THE SAP. DEMAND THE MCID AND HOW MANY PFS EVENTS NEEDED TO DO ANALYSIS!!!

0 · Reply

laaarsas May. 7 at 1:31 PM

$AVBP They hide SAP. Effing lunatics. This trial is the riskiest of many.

0 · Reply

Timefortendies77 Apr. 30 at 6:23 PM

$AVBP ArriVent BioPharma (AVBP) defines "mid-2026" as the period spanning approximately May through August 2026.

0 · Reply

judgeyoung2 Apr. 24 at 8:03 PM

$AVBP the way this has been trading + elevated volume suggests it’s coming soon

0 · Reply

justiceforb_85 Apr. 22 at 8:55 PM

$AVBP nice build up to firmonertinib data release. If trial unsuccessful, there still is ALPACCA trial.

0 · Reply

BlackWebX Apr. 21 at 12:32 PM

$AVBP

0 · Reply

laaarsas Apr. 16 at 12:28 PM

$AVBP no one cares fine go lose your money

0 · Reply

laaarsas Apr. 16 at 12:15 PM

$AVBP so weak and scammy not to publish the SAP. Clowns.

0 · Reply

laaarsas Apr. 16 at 12:11 PM

$AVBP they don’t tell us. Where is the SAP. Goddamn it where is it???

0 · Reply

laaarsas Apr. 16 at 12:00 PM

$AVBP fkn scam company not replying to email. HOW MANY EVENTS ARE NEEDED FO READOUT? HOW IS THE STUDY POWERED?? TELL US

0 · Reply

Monkey7779192 Apr. 9 at 9:29 AM

$AVBP When did they delay data and why?

2 · Reply

baliosxantos Apr. 8 at 9:07 PM

$AVBP

0 · Reply

Market Cap	1.26B
Revenue (ttm)	0.00
Net Income (ttm)	-166.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,309,800
Avg Vol	472,164
Day's Range	N/A - N/A
Shares Out	46.58M
Stochastic %K	88%
Beta	1.51
Analysts	Strong Sell
Price Target	$43.92